Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL, Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L; ECOSPOR IV Investigators. Sims MD, et al. JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758. JAMA Netw Open. 2023. PMID: 36780159 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis.
Abell TL, Kuo B, Esfandyari T, Pfeifer ND, Grimaldi M, Renzulli C, Tacchi R, Zhou K, Barnes CN, Nguyen DD, Nguyen L, Talley NJ, McCallum R. Abell TL, et al. Among authors: esfandyari t. Neurogastroenterol Motil. 2023 Apr;35(4):e14523. doi: 10.1111/nmo.14523. Epub 2023 Jan 9. Neurogastroenterol Motil. 2023. PMID: 36624727 Clinical Trial.
Cancer stem cells, the ultimate targets in cancer therapy.
Shabbir A, Esfandyari T, Farassati F. Shabbir A, et al. Among authors: esfandyari t. Onco Targets Ther. 2018 Jan 3;11:183-184. doi: 10.2147/OTT.S154431. eCollection 2018. Onco Targets Ther. 2018. PMID: 29379299 Free PMC article. No abstract available.
Ral signaling pathway in health and cancer.
Moghadam AR, Patrad E, Tafsiri E, Peng W, Fangman B, Pluard TJ, Accurso A, Salacz M, Shah K, Ricke B, Bi D, Kimura K, Graves L, Najad MK, Dolatkhah R, Sanaat Z, Yazdi M, Tavakolinia N, Mazani M, Amani M, Ghavami S, Gartell R, Reilly C, Naima Z, Esfandyari T, Farassati F. Moghadam AR, et al. Among authors: esfandyari t. Cancer Med. 2017 Dec;6(12):2998-3013. doi: 10.1002/cam4.1105. Epub 2017 Oct 18. Cancer Med. 2017. PMID: 29047224 Free PMC article. Review.
RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).
Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, Peng W, Rouyanian A, Asvadi Kermani A, Soleimani M, Patrad E, Lialyte K, Wang K, Williamson S, Abdulkarim B, Olyaee M, Farassati F. Ezzeldin M, et al. Among authors: esfandyari t. Mol Oncol. 2014 Jul;8(5):1043-53. doi: 10.1016/j.molonc.2014.03.020. Epub 2014 Apr 13. Mol Oncol. 2014. PMID: 24785097 Free PMC article.
Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis.
McCallum RW, Lembo A, Esfandyari T, Bhandari BR, Ejskjaer N, Cosentino C, Helton N, Mondou E, Quinn J, Rousseau F; TZP-102 Phase 2b Study Group. McCallum RW, et al. Among authors: esfandyari t. Neurogastroenterol Motil. 2013 Nov;25(11):e705-17. doi: 10.1111/nmo.12184. Epub 2013 Jul 15. Neurogastroenterol Motil. 2013. PMID: 23848826 Clinical Trial.
28 results